Welcome to our dedicated page for Dswiss SEC filings (Ticker: DQWS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DSWISS Inc (DQWS) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a Nevada-incorporated issuer. These filings offer insight into how DSWISS reports material corporate events, governance changes, and other information relevant to its operations in biotech-nutraceuticals, medical consumables, and beauty supplies.
As an SEC-reporting company, DSWISS submits forms such as the Form 8-K to describe significant developments. For example, an 8-K filing reported the resignation of director Sui Ting Wong and noted that, following this event, Leong Ming Chia became the sole director of the company. Details like the company’s jurisdiction of incorporation and the location of its principal executive offices in Kuala Lumpur, Malaysia are also reflected in such filings.
On this page, users can review DSWISS’s periodic and current reports, including 10-K annual reports and 10-Q quarterly reports when filed, as well as Forms 8-K and other submissions. These documents help explain the company’s structure, risk disclosures, and key events affecting shareholders. For those interested in governance and oversight, filings may also discuss board composition, officer roles, and other corporate matters.
Stock Titan enhances access to these documents with AI-powered summaries that highlight important sections and clarify complex language. Instead of reading entire filings line by line, users can quickly see the main points of DSWISS’s reports, then open the full text for deeper analysis. Real-time updates from EDGAR ensure that new DQWS filings appear promptly, while forms related to insider activity, executive changes, and other regulatory topics can be reviewed in one place.
DSwiss, Inc. (DQWS) reported a small net loss for 2025 as revenue declined modestly and margins compressed. The company generated $2,920,986 in revenue for the year ended December 31, 2025, down 6.16% from 2024, mainly from OEM/ODM nutraceutical and skincare sales.
Gross profit was $564,562, with gross margin easing to 19.33% from 20.02%. DSwiss moved from a prior-year net profit of $22,223 to a net loss of $76,860, increasing accumulated losses to $1,464,790. Liquidity weakened, with a working capital deficit of $133,691 and cash of $285,034 at year-end, versus prior surplus and higher cash.
The Nevada-based nutraceutical and skincare OEM/ODM operator continues to focus on Asia-Pacific markets while re-entering international markets such as China and the United States. It is investing in R&D, talent expansion and M&A opportunities, while acknowledging material weaknesses in internal controls and outlining remediation plans.
DSwiss, Inc. (DQWS) filed its Q3 2025 10-Q, reporting softer quarterly results and a going concern warning. Q3 revenue was $441,618 versus $1,027,198 a year ago, with a net loss of $97,891 compared to a loss of $61,468 last year. Gross profit for the quarter was $58,569.
For the nine months ended September 30, 2025, revenue reached $2,464,144 and net income was $72,973. Operating cash flow was $(18,597). Cash and cash equivalents were $367,519. Total assets were $800,748 and total liabilities were $652,155, resulting in equity of $148,593. Shares outstanding were 206,904,585 as of September 30, 2025.
Management disclosed substantial doubt about the Company’s ability to continue as a going concern due to accumulated deficit and negative operating cash flow. Customer concentration was high, with one customer accounting for 67% of Q3 revenue. Internal controls were deemed not effective due to material weaknesses. The Company recognized an operating lease right‑of‑use asset of $156,014 following a new office lease commencing March 1, 2025.
DSwiss, Inc. reported a board change, with director Sui Ting Wong resigning on October 1, 2025. Following this resignation, Leong Ming Chia became the company’s sole director. He already serves as President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and Director, concentrating both management and board oversight roles in a single individual. The company also recorded a written consent of the board dated October 1, 2025 to reflect this change.